ZUG, SWITZERLAND--(Business Wire / Korea Newswire)--Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL - frown lines) and lateral canthal lines (LCL - crow’s feet). Both studies met their primary endpoints, demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, significantly improves both frown lines and crow’s feet, with a rapid onset of action as early as day one and long duration.[1,2]
“These results provide an additional layer of confidence in the long-lasting efficacy, speed and convenience of RelabotulinumtoxinA, which not only represents the innovation of our neuromodulator portfolio, but also demonstrates our commitment to responding to the real needs of healthcare professionals and patients.” BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
43QM2106 is a phase IIIb, randomized, double-blind, placebo-controlled trial to assess the aesthetic improvement and onset of action of RelabotulinumtoxinA in patients with moderate to severe frown lines. The trial met its primary endpoint, with 92.9% of those treated with RelabotulinumtoxinA rating their frown lines as ‘improved’ or better on the Global Aesthetic Improvement Scale (GAIS) at month one, compared to 9.1% of those treated with placebo (P News provided byGalderma Distribution Channel Health Pharmaceutical Hospitals/Healthcare Development Overseas